Medical Policy Update for August 23, 2022
Medical Guidelines | Reason for Update |
---|---|
Capsule Endoscopy, Wireless (PDF) | Typo corrected under When Not Covered section. No change to policy statement. |
Diagnosis of Vaginitis including Multi-target PCR Testing AHS – M2057 (PDF) | Added the following statement to When Not Covered section “Reimbursement is not allowed for screening of bacterial vaginosis using Aptima BV.” Medical Director review 8/2022. |
Facet Joint Denervation (PDF) | Criteria moved from Policy Guidelines section to When Covered section for clarity. No change to policy statement. Medical Director review 8/2022. |
Quantose Impaired Glucose Tolerance (IGT) Test AHS - G2135 | Test no longer available. Medical director review. Policy archived. |
Therapeutic Radiopharmaceuticals in Oncology (PDF) | Policy statement updated to include coverage of Lutetium 177 (Lu 177) vipivotide tetraxetan (Pluvicto). No change to policy intent. Medical Director review 8/2022. |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.